[Ruxolitinib combined with venetoclax and azacitidine in the treatment of refractory T-ALL patients with JAK1, JAK3, and STAT5B gene mutations: a case report and literature review].

Peipei Xu(Nanjing Drum Tower Hospital), B Chen(Nanjing Drum Tower Hospital), Jian Ouyang(Nanjing Drum Tower Hospital), Tong Zhou(Xiamen University), Y Y Xu(Nanjing Drum Tower Hospital), Miao Peng(Central South University), Ting Xie(Sun Yat-sen University), Yang Du(State Key Laboratory of Gas Disaster Detecting, Preventing and Emergency Controlling), Yihua Yang(Nanjing Drum Tower Hospital)
Cited by 1


Related Papers